Merck Serono, the biopharmaceutical business of Merck, and Intrexon Corporation, today announced an exclusive strategic collaboration and license agreement to develop and commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies.
from The Medical News http://ift.tt/1ErEiew
from The Medical News http://ift.tt/1ErEiew
No comments:
Post a Comment